SCHEMBL26075693

SCHEMBL26075693

CCOc1ccc(-c2ccc(-c3cc(C)c4cc(C(F)(F)F)ccc4n3)nc2)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 3/20 0.42
▸ MCHR1 Q99705 1/20 0.39
▸ PPARD Q03181 5/20 0.39
▸ TP53 P04637 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ ALOX5AP P20292 1/20 0.38
▸ FEN1 P39748 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26074055 0.82 LMNA (0.47) MCHR1PPARDTP53LMNAHTR2B
SCHEMBL26075411 0.82 HMOX1 (0.42) MCHR1PPARDTP53LMNAHTR2B
SCHEMBL23590148 0.81 KDM4E (0.51) DGAT1TP53LMNAALOX5APFEN1
SCHEMBL26075292 0.80 FEN1 (0.41) MCHR1TP53LMNAHTR2BALOX5AP
SCHEMBL26075691 0.80 ACP1 (0.42) DGAT1LMNAALOX5APFEN1KDM4E
SCHEMBL26075703 0.79 CBFB (0.43) DGAT1MCHR1HTR2B
SCHEMBL23590219 0.78 KDM4E (0.55) TP53LMNAKDM4ESMN1; SMN2HSD17B10
SCHEMBL26075595 0.78 MAP4K4 (0.45) TP53LMNAKDM4ESMN1; SMN2MEN1
SCHEMBL26075701 0.78 MCHR1 (0.40) DGAT1MCHR1HTR2BALOX5APFEN1
SCHEMBL26075379 0.77 PTGS2 (0.44) TP53LMNAALOX5APFEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD DGAT1 230/4885MCHR1 3681/4885PPARD 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback